Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cilostazol
Drug ID BADD_D00466
Description Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Indications and Usage Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
Marketing Status approved; investigational
ATC Code B01AC23
DrugBank ID DB01166
KEGG ID D01896
MeSH ID D000077407
PubChem ID 2754
TTD Drug ID D03VPC
NDC Product Code 70518-2208; 66039-113; 50268-177; 0054-0028; 46438-0633; 0093-2065; 70436-157; 0054-0044; 63629-8795; 71610-037; 70436-156; 46438-1109; 42291-453; 50090-5329; 60505-2521; 58175-0379; 63415-0034; 60505-2522; 63629-8796; 72189-116; 46438-0632; 50268-176; 70518-2714; 42185-7038; 0093-2064
UNII N7Z035406B
Synonyms Cilostazol | 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone | OPC 13013 | OPC-13013 | Pletal
Chemical Information
Molecular Formula C20H27N5O2
CAS Registry Number 73963-72-1
SMILES C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Retroperitoneal haemorrhage12.01.17.018; 24.07.01.017; 07.07.02.002--
Rhinitis22.07.03.006; 11.01.13.004--
Shock24.06.02.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Skin hypertrophy23.01.04.002--Not Available
Stevens-Johnson syndrome11.07.01.005; 10.01.01.045; 23.03.01.007; 12.03.01.014--
Subarachnoid haemorrhage24.07.04.004; 17.08.01.010; 12.01.10.0110.000450%Not Available
Subdural haematoma17.08.05.002; 12.01.10.003; 24.07.04.005--Not Available
Supraventricular tachycardia02.03.03.012--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000300%
Tachycardia02.03.02.0070.000450%Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.006--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tooth abscess11.01.04.003; 07.09.01.003--Not Available
Torsade de pointes02.03.04.005--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.000300%
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection21.14.02.002; 11.01.10.002--
Varicose vein24.10.04.001--Not Available
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Ventricular extrasystoles02.03.04.0070.000300%Not Available
Ventricular fibrillation02.03.04.0080.000600%
Ventricular tachycardia02.03.04.0100.000660%
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.0030.000750%
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages